Back to 
ZACKS INVESTMENT MANAGEMENT
ZACKS INVESTMENT MANAGEMENT
TRVI2 quarters
Position history for ZACKS INVESTMENT MANAGEMENT's holdings in TREVI THERAPEUTICS INC
No. Zacks Investment Management exited its TRVI (Trevi Therapeutics) position in Q3 2023. Its Q2 2023 13F listed 10,000 shares worth $23,900. Zacks Investment Management first reported TRVI in Q2 2023 and held it in 1 quarterly 13F filing.
Final Value
$0
Final Shares
0
Total Value Change
-$23,900
Total Shares Change
-10,000
Quarter-by-Quarter History
Other major holders of TRVI: FMR LLC, BlackRock, Inc., WELLINGTON MANAGEMENT GROUP LLP